Literature DB >> 24337845

Reversal effect of BM-cyclin 1 on multidrug resistance by down-regulating MRP2 in BALB/C nude mice bearing C-A120 cells.

Lin Wang1, Xiaoyun Li2, Gaofeng Jiang3, Jizhen Liang1, Yan Sun4, Wei Liu5.   

Abstract

Our previous study demonstrated that BM-cyclin 1, a traditional anti-mycoplasma drug, could effectively reverse the multidrug resistance (MDR) of C-A120 cells. The present study aims to explore the reversal effect of BM-cyclin 1 on MDR and its mechanisms in BALB/C nude mice bearing C-A120 cells. Immunoblotting analysis and reverse transcription-polymerase chain reaction (RT-PCR) were used to study the change in multidrug resistance-associated protein 2 (MRP2) induced by BM-cyclin 1. We found that the expression levels of MRP2 protein and mRNA in C-A120 cells treated with BM-cyclin 1 were reduced significantly. Chemical colorimetry revealed no significant change in the level of glutathione (GSH). In the xenograft model, the inhibitory rate of C-A120 cells growth in BM-cyclin 1 plus adriamycin (ADM) group was 52%, which was significantly higher than in control group (P<0.01). The immunoblotting and RT-PCR results conclusively demonstrated that BM-cycin 1 could significantly reduce the expression of MRP2 in transplanted tumor. In conclusion, BM-cyclin 1 could effectively reverse the MDR of C-A120 cells in vivo by suppressing the expression of MRP2.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24337845     DOI: 10.1007/s11596-013-1208-6

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  21 in total

1.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines.

Authors:  M Kool; M de Haas; G L Scheffer; R J Scheper; M J van Eijk; J A Juijn; F Baas; P Borst
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

Review 2.  Overview: ABC transporters and human disease.

Authors:  M M Gottesman; S V Ambudkar
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

Review 3.  The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs.

Authors:  Karolina M Stępień; Michał Tomaszewski; Joanna Tomaszewska; Stanisław J Czuczwar
Journal:  Pharmacol Rep       Date:  2012       Impact factor: 3.024

Review 4.  Mammalian multidrug-resistance proteins (MRPs).

Authors:  Andrew J Slot; Steven V Molinski; Susan P C Cole
Journal:  Essays Biochem       Date:  2011-09-07       Impact factor: 8.000

Review 5.  Efflux pump inhibitors: a strategy to combat P-glycoprotein and the NorA multidrug resistance pump.

Authors:  Ling Zhang; Shutao Ma
Journal:  ChemMedChem       Date:  2010-06-07       Impact factor: 3.466

6.  Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPARgamma activation by troglitazone.

Authors:  Qing Chen; Jie Zhou; Chunfang Jiang; Juan Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-06-17

Review 7.  [Multidrug resistance].

Authors:  G H Mickisch
Journal:  Urologe A       Date:  1996-09       Impact factor: 0.639

Review 8.  Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.

Authors:  Hilary Thomas; Helen M Coley
Journal:  Cancer Control       Date:  2003 Mar-Apr       Impact factor: 3.302

Review 9.  Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.

Authors:  Alex Sparreboom; Romano Danesi; Yuichi Ando; Juliana Chan; William D Figg
Journal:  Drug Resist Updat       Date:  2003-04       Impact factor: 18.500

Review 10.  Current status on marine products with reversal effect on cancer multidrug resistance.

Authors:  Ioana Abraham; Khalid El Sayed; Zhe-Sheng Chen; Huiqin Guo
Journal:  Mar Drugs       Date:  2012-10-19       Impact factor: 6.085

View more
  3 in total

1.  Biological effects of novel "combi-targeting" molecule and its effect on DNA repair pathway in hormone-refractory prostate cancer.

Authors:  Youqiang Fang; Jieying Wu; Tengcheng Li; Yun Luo; Qiyu Qiu; Xinxin Quan; Li Gao; Wei Liu
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

2.  Inhibition of prostate cancer growth by solanine requires the suppression of cell cycle proteins and the activation of ROS/P38 signaling pathway.

Authors:  Bin Pan; Weifeng Zhong; Zhihai Deng; Caiyong Lai; Jing Chu; Genlong Jiao; Junfeng Liu; Qizhao Zhou
Journal:  Cancer Med       Date:  2016-10-10       Impact factor: 4.452

3.  DRP5 is involved in cancer cell growth and predicts poor prognosis in human osteosarcoma.

Authors:  Lin Wang; Weihai Liu; Hengtao Tang; Xianbiao Xie; Changye Zou; Yongqian Wang; Zhenhua Gao; Junqiang Yin
Journal:  Cancer Med       Date:  2017-04-04       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.